JP7014731B2 - 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法 - Google Patents

置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法 Download PDF

Info

Publication number
JP7014731B2
JP7014731B2 JP2018551358A JP2018551358A JP7014731B2 JP 7014731 B2 JP7014731 B2 JP 7014731B2 JP 2018551358 A JP2018551358 A JP 2018551358A JP 2018551358 A JP2018551358 A JP 2018551358A JP 7014731 B2 JP7014731 B2 JP 7014731B2
Authority
JP
Japan
Prior art keywords
purine
cyclohexanecarboxamide
ylamino
chloro
difluorophenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018551358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510066A (ja
JP2019510066A5 (https=
Inventor
エフ． ボーイラン ジョン
エル． ブライ ゴードン
フィルバロフ エレン
フバード ロバート
ミコロン デビッド
レイモン ヘザー
シ タオ
エム． トラン タム
俊也 辻
エル． ウォン リリー
シュ スイチャン
ズー ダン
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2019510066A publication Critical patent/JP2019510066A/ja
Publication of JP2019510066A5 publication Critical patent/JP2019510066A5/ja
Application granted granted Critical
Publication of JP7014731B2 publication Critical patent/JP7014731B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018551358A 2016-04-01 2017-03-31 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法 Active JP7014731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317412P 2016-04-01 2016-04-01
US62/317,412 2016-04-01
PCT/US2017/025252 WO2017173206A1 (en) 2016-04-01 2017-03-31 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (3)

Publication Number Publication Date
JP2019510066A JP2019510066A (ja) 2019-04-11
JP2019510066A5 JP2019510066A5 (https=) 2020-05-07
JP7014731B2 true JP7014731B2 (ja) 2022-02-01

Family

ID=59959573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018551358A Active JP7014731B2 (ja) 2016-04-01 2017-03-31 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法

Country Status (15)

Country Link
US (1) US10576085B2 (https=)
EP (1) EP3436018A4 (https=)
JP (1) JP7014731B2 (https=)
KR (1) KR102356433B1 (https=)
CN (1) CN109069512B (https=)
AU (1) AU2017241837B2 (https=)
BR (1) BR112018070163A2 (https=)
CA (1) CA3018986A1 (https=)
CL (1) CL2018002787A1 (https=)
EA (1) EA039392B1 (https=)
IL (1) IL262007B2 (https=)
MX (1) MX379513B (https=)
NZ (1) NZ746554A (https=)
SG (2) SG11201808388QA (https=)
WO (1) WO2017173206A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
BR112018068676A2 (pt) 2016-03-31 2019-01-15 Janssen Pharmaceuticals Inc derivados de indol substituídos como inibidores da replicação viral do dengue
BR112018069601A2 (pt) 2016-03-31 2019-01-29 Janssen Pharmaceuticals Inc derivados de indolina substituídos como inibidores da replicação viral da dengue
HUE056631T2 (hu) 2016-04-01 2022-02-28 Signal Pharm Llc (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
EP3630723B1 (en) 2017-05-22 2022-08-24 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
AU2018345647A1 (en) 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
EP3833372A4 (en) * 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
MX2021012638A (es) * 2019-04-16 2022-01-04 Vivace Therapeutics Inc Compuestos biciclicos.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021102204A1 (en) * 2019-11-20 2021-05-27 Vivace Therapeutics, Inc. Heteroaryl compounds
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
KR102664454B1 (ko) * 2021-08-03 2024-05-09 한국생명공학연구원 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용
CN114681456A (zh) * 2022-02-23 2022-07-01 中山大学附属第六医院 Plx3397在结直肠癌的治疗中的用途
EP4703725A1 (en) 2024-08-29 2026-03-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Modulators of the mitotic cell cycle in cancer cells and uses thereof for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526989A (ja) 2005-01-13 2008-07-24 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2009535346A (ja) 2006-04-26 2009-10-01 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物及びそれによる治療方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
AU2004309420B2 (en) * 2003-12-23 2008-10-30 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
WO2007062338A2 (en) 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
WO2007134298A2 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
CA2667345C (en) 2006-10-27 2016-03-22 Signal Pharmaceuticals, Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9512124B2 (en) * 2014-10-06 2016-12-06 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CN115131834A (zh) * 2015-08-13 2022-09-30 小米科技有限责任公司 移动设备及其屏幕模组、指纹采集方法、装置及电子设备
HUE056631T2 (hu) * 2016-04-01 2022-02-28 Signal Pharm Llc (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526989A (ja) 2005-01-13 2008-07-24 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物、およびそれによる治療の方法
JP2009535346A (ja) 2006-04-26 2009-10-01 シグナル ファーマシューティカルズ，エルエルシー ハロアリール置換アミノプリン、その組成物及びそれによる治療方法

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BLOOD，2010年，116(13)，pp.2286-2294
Cancer Immunol Immunother，2010年，59，pp.1839-1849
Cancer Res，2006年，66(2)，pp.999-1006
Dokkyo Journal of Medical Sciences，2005年，32(3)，pp.255-263
J Enzyme Inhib Med Chem，2015年，30(4)，pp.679-687
Japanese Journal of Lung Cancer，2009年，49(4)，pp.416-421
Med Pediatr Oncol，2002年，39，pp.530-535
Mol Cancer Ther，2015年，14(4)，pp.847-856
Molecular Oncology，2008年，1，pp.395-405
Pigment Cell Melanoma Res，2010年，23，pp.430-440
信州医誌，2007年，55(1)，pp.3-9
日消誌，1991年，88(8)，pp.1539-1544

Also Published As

Publication number Publication date
BR112018070163A2 (pt) 2019-01-29
MX2018011992A (es) 2019-01-24
KR20180126497A (ko) 2018-11-27
MX379513B (es) 2025-03-11
EA201892229A1 (ru) 2019-03-29
CN109069512A (zh) 2018-12-21
NZ746554A (en) 2023-03-31
EA039392B1 (ru) 2022-01-21
AU2017241837B2 (en) 2021-07-22
CN109069512B (zh) 2022-06-14
CA3018986A1 (en) 2017-10-05
JP2019510066A (ja) 2019-04-11
CL2018002787A1 (es) 2019-01-18
EP3436018A4 (en) 2019-11-13
WO2017173206A1 (en) 2017-10-05
IL262007B (en) 2022-12-01
IL262007A (en) 2018-10-31
IL262007B2 (en) 2023-04-01
SG10202009589UA (en) 2020-10-29
US20170281633A1 (en) 2017-10-05
SG11201808388QA (en) 2018-10-30
KR102356433B1 (ko) 2022-01-27
US10576085B2 (en) 2020-03-03
EP3436018A1 (en) 2019-02-06
AU2017241837A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
AU2014254056B2 (en) Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
AU2014253978B2 (en) Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
US10004735B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
US9782427B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
JP6995058B2 (ja) （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法
CA2909579A1 (en) Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
EP3131550B1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy with a histone deacetylase inhibitor
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629859B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1233943B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1233943A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220120

R150 Certificate of patent or registration of utility model

Ref document number: 7014731

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250